The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Al Moghrabi, Nisreen ^a   Nofel, Asmaa ^a   Al Yousef, Nujoud ^a   Madkhali, Safia ^a   Bin Amer, Suad M ^a   Alaiya, Ayodele ^a   Shinwari, Zakia ^a   Al Tweigeri, Taher ^a   Karakas, Bedri ^a   Tulbah, Asma ^a   Aboussekhra, Abdelilah ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

BRCA1; Breast cancer; Gene expression; Methylation; White blood cells

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LEUKOCYTE; MAJOR CLINICAL STUDY; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; ADOLESCENT; BREAST TUMOR; CANCER GRADING; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; HETEROZYGOTE; MAMMARY GLAND; METABOLISM; PATHOLOGY; YOUNG ADULT;

BRCA1 PROTEIN; TRANSCRIPTOME;

ADOLESCENT; ADULT; AGED; BRCA1 PROTEIN; BREAST NEOPLASMS; CLUSTER ANALYSIS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; HETEROZYGOTE; HUMANS; LEUKOCYTES; MAMMARY GLANDS, HUMAN; MIDDLE AGED; NEOPLASM GRADING; PROMOTER REGIONS, GENETIC; TRANSCRIPTOME; YOUNG ADULT;

EID: 84964314605     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-830     Document Type: Article

References (43)

1. Wolffe AP, Matzke MA: Epigenetics: regulation through repression. Science 1999, 286:481-486.
2. Cropley JE, Martin DI, Suter CM: Germline epimutation in humans. Pharmacogenomics 2008, 9(12):1861-1868.
3. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev 2002, 3(6):415-428.
4. Chong S, Youngson NA, Whitelaw E: Heritable germline epimutation is not the same as transgenerational epigenetic inheritance. Nat Genet 2007, 39(5):574-575. author reply 575-576.
5. Horsthemke B: Heritable germline epimutations in humans. Nat Genet 2007, 39(5):573-574. author reply 575-576.
6. Suter CM, Martin DI: Inherited epimutation or a haplotypic basis for the propensity to silence? Nat Genet 2007, 39(5):573. author reply 576.
7. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, DingW, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (New York, NY) 1994, 266(5182):66-71.
8. Arver B, Du Q, Chen J, Luo L, Lindblom A: Hereditary breast cancer: a review. Semin Cancer Biol 2000, 10(4):271-288.
9. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE: Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006, 8(4):R38.
10. Butcher DT, Rodenhiser DI: Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. Eur J Cancer 2007, 43(1):210-219.
11. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Sauter G: Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344(8):539-548.
12. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536.
13. Snell C, Krypuy M, Wong EM, Con Fabi K, Loughrey MB, Dobrovic A: BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res 2008, 10(1):R12.
14. Al-Moghrabi N, Al-Qasem AJ, Aboussekhra A: Methylation-related mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women. Int J Oncol 2011, 39(1):129-135.
15. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, Trojan J, Vaurs-Barrière C, Bignon YJ, Ramus S, Benitez J, Caldes T, Akiyama Y, Yuasa Y, Launonen V, Canal MJ, Rodriguez R, Capella G, Peinado MA, Borg A, Aaltonen LA, Ponder BA, Baylin SB, Herman JG: DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001, 10(26):3001-3007.
16. Esteller M: Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 2000, 36(18):2294-2300.
17. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000, 92(7):564-569.
18. Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S: BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat 2011, 129(1):69-77.
19. Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, Giles GG, Hopper JL, Dobrovic A: Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) 2011, 4(1):23-33.
20. Hansmann T, Pliushch G, Leubner M, Kroll P, Endt D, Gehrig A, Preisler-Adams S, Wieacker P, Haaf T: Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer. Hum Mol Genet 2012, 21(21):4669-4679.
21. Pejovic T, Yates JE, Liu HY, Hays LE, Akkari Y, Torimaru Y, Keeble W, Rathbun RK, Rodgers WH, Bale AE, Ameziane N, Zwaan CM, Errami A, Thuillier P, Cappuccini F, Olson SB, Cain JM, Bagby GC Jr: Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer. Cancer Res 2006, 66(18):9017-9025.
22. Wetzig A, Alaiya A, Al-Alwan M, Pradez CB, Pulicat MS, Al-Mazrou A, Shinwari Z, Sleiman GM, Ghebeh H, Al-Humaidan H, Gaafar A, Kanaan I, Adra C: Differential marker expression by cultures rich in mesenchymal stem cells. BMC Cell Biol 2013, 14:54.
23. Alaiya A, Fox J, Bobis S, Matic G, Shinwari Z, Barhoush E, Marquez M, Nilsson S, Holmberg AAR: Proteomic analysis of soft tissue tumor implants treated with a novel polybisphosphonate. Cancer Genomics Proteomics 2014, 11:39-50.
24. Li GZ, Vissers JP, Silva JC, Golick D, Gorenstein MV, Geromanos SJ: Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics 2009, 9(6):1696-1719.
25. Wojdacz TK, Thestrup BB, Overgaard J, Hansen LL: Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events. Diagn Pathol 2011, 6:116.
26. Wales MM, Biel MA, El Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB: p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1995, 1(6):570-577.
27. Guilford PJ, Hopkins JB, Grady WM, Markowitz SD, Willis J, Lynch H, Rajput A, Wiesner GL, Lindor NM, Burgart LJ, Toro TT, Lee D, Limacher JM, Shaw DW, Findlay MP, Reeve AE: E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 1999, 14(3):249-255.
28. Lee SW: H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med 1996, 2(7):776-782.
29. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995, 375(6531):503-506.
30. Pegg AE: Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990, 50(19):6119-6129.
31. Srinivasula SM, Poyet JL, Razmara M, Datta P, Zhang Z, Alnemri ES: The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem 2002, 277(24):21119-21122.
32. Ashkenazi A: Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat Rev Cancer 2002, 2(6):420-430.
33. Yang R, Muller C, Huynh V, Fung YK, Yee AS, Koeffler HP: Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins. Mol Cell Biol 1999, 19(3):2400-2407.
34. Knudson AG: Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996, 122(3):135-140.
35. Angele S, Hall J: The ATM gene and breast cancer: is it really a risk factor? Mutat Res 2000, 462(2-3):167-178.
36. Waha A, Sturne C, Kessler A, Koch A, Kreyer E, Fimmers R, Wiestler OD, von Deimling A, Krebs D, Schmutzler RK: Expression of the ATM gene is significantly reduced in sporadic breast carcinomas. Int J Cancer 1998, 78(3):306-309.
37. Clarke RA, Kairouz R, Watters D, Lavin MF, Kearsley JH, Lee CS: Upregulation of ATM in sclerosing adenosis of the breast. Mol Pathol 1998, 51(4):224-226.
38. Jensen RA, Page DL, Dupont WD, Rogers LW: Invasive breast cancer risk in women with sclerosing adenosis. Cancer 1989, 64(10):1977-1983.
39. Tamimi RM, Colditz GA, Wang Y, Collins LC, Hu R, Rosner B, Irie HY, Connolly JL, Schnitt SJ: Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat 2011, 128(1):243-250.
40. Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D: Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 2000, 89(6):506-513.
41. Karakolev: Expression of insuline-like growth factor-1 receptor mrna in colorectal carcinoma patients. Biotechnol Biotec Eq SPECIAL EDITION/ON-LINE 2011, 26(Number 1):89-95.
42. Chen J, Anderson M, Misek DE, Simeone DM, Lubman DM: Characterization of apolipoprotein and apolipoprotein precursors in pancreatic cancer serum samples via two-dimensional liquid chromatography and mass spectrometry. J Chromatogr A 2007, 1162(2):117-125.
43. Honda K, Okusaka T, Felix K, Nakamori S, Sata N, Nagai H, Ioka T, Tsuchida A, Shimahara T, Shimahara M, Yasunami Y, Kuwabara H, Sakuma T, Otsuka Y, Ota N, Shitashige M, Kosuge T, Büchler MW, Yamada T: Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. PLoS One 2012, 7(10):e46908.